# Olanzapine

## Okpine F.C. 5mg

| 藥物代碼 | OOKP |
| :--- | :--- |
| 適應症 | Treatment of the manifestations of schizophrenia; treatment of acute or mixed mania episodes associated with bipolar I disorder \(as monotherapy or in combination with lithium or valproate\); maintenance treatment of bipolar I disorder; in combination with fluoxetine for treatment-resistant or bipolar I depression. |
| 副作用 | &gt;10%:Cardiovascular: Orthostatic hypotension \(3-20%\)Central nervous system: Drowsiness\(20-39%\), extrapyramidal reaction \(10-32%\), akathisia \(3-27%\), parkinsonian-like syndrome \(14% to 20%\), dizziness \(8-11%\), headache \(adolescents 17%\), fatigue \(2% to 14%\), insomnia \(12%\)Endocrine & metabolic: Increased serum prolactin \(30-47%\), weight gain \(5-40%\)Gastrointestinal: Increased appetite \(3-29%\), xerostomia \(3-22%\), dyspepsia \(3-11%\), constipation \(4-11%\)Hepatic: Increased serum AST \(adolescents 28%\), decreased serum bilirubin \(adolescents 22%\), increased serum ALT \(?3 x ULN; adolescents and adults 5% to 12%\)Neuromuscular & skeletal: Weakness \(8-20%\)Miscellaneous: Accidental injury \(12%\) |
| 禁忌 | Hypersensitivity to olanzapine or any component of the formulation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Schizophrenia:  Oral: Initial: 5 to 10 mg once daily \(increase to 10 mg once daily within 5 to 7 days\) Bipolar I: Oral: Monotherapy: Initial: 10 to 15 mg once daily; increase by 5 mg daily at intervals of not less than 24 hours. Maintenance: 5 to 20 mg daily; recommended maximum dose: 20 mg daily. |
| 肝功能異常 | 無需調整劑量  肝功能中度不全的病患 \(肝硬化、Child-Pugh A或B類肝炎 \)，其起始劑量應為5毫克，欲增加劑量時須謹慎 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Compatible - maternal benefit &gt;&gt; embryo-fetal risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

